欧洲机械循环支持患者登记(EUROMACS):首份EUROMACS儿科(Paedi-EUROMACS)报告
EUROMACS为EACTS旗下登记库,本报告分析2000年1月1日至2017年12月31日期间25家医院237例儿科(≤19岁)机械循环支持植入数据,共210例患者(81女,129男)。最常见诊断为心肌病(71.4%),其次为先天性心脏病(18.6%);平均支持时间11.6个月(±16.5标准差)。12个月时38%接受移植、7%撤除装置、15%死亡;24个月时51%接受移植、17%在支持中死亡、22%仍在装置上、9%因心肌恢复拔除。装置故障(含血栓所致泵腔更换)为最常见不良事件。
要点
- 儿科EUROMACS报告纳入25家医院237例植入、210例患者(≤19岁),平均支持时间11.6个月(±16.5标准差)。
- 12个月时38%接受移植、7%撤除装置、15%死亡;24个月时51%接受移植、17%在支持中死亡、22%仍在装置上、9%因心肌恢复拔除。
- 植入后前3个月每100患者月不良事件率:装置故障11.97、大出血2.83、大感染2.83、神经系统事件1.52。
核心结论
- 首份儿科EUROMACS报告显示欧洲国家植入后2年内移植率低于美国数据,1年生存率似乎令人满意,装置故障(含血栓所致泵腔更换)为最常见不良事件。
研究设计与样本
- EUROMACS为欧洲心胸外科协会(EACTS)旗下登记库,参与医院提交机械循环支持植入的术前、围术期及长期术后数据。
- 分析2000年1月1日至2017年12月31日期间所有≤19岁儿科患者的植入数据,报告包含患者特征、植入频率、结局(含死亡率、移植率与恢复率)及不良事件更新。
主要发现
- 25家医院贡献237例植入、210例患者(81女,129男)。
- 最常见诊断为任何形式的心肌病(71.4%),其次为先天性心脏病(18.6%)。
- 总体平均装置支持时间为11.6个月(±16.5标准差)。
- 173例儿童(82.4%)存活至移植、恢复或仍在支持中;37例(17.6%)在观察随访期内于支持中死亡。
- 12个月时38%接受移植、7%撤除装置、15%死亡;24个月时51%接受移植、17%在支持中死亡、22%仍在装置上、9%因心肌恢复拔除。
关键数值与推荐
- 植入后前3个月内每100患者月不良事件率:装置故障11.97、大出血2.83、大感染2.83、神经系统事件1.52。
- 12个月时38%接受移植、7%撤除装置、15%死亡。
- 24个月时51%接受移植、17%在支持中死亡、22%仍在装置上、9%因心肌恢复拔除。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: EUROMACS is a registry of the European Association for Cardio-Thoracic Surgery (EACTS) whose purpose is to gather clinical data related to durable mechanical circulatory support for scientific purposes and to publish annual reports. Because the treatment of children with end-stage heart failure has several significantly different characteristics than the treatment of adults, data and outcomes of interventions are analysed in this dedicated paediatric report. METHODS: Participating hospitals contributed pre-, peri- and long-term postoperative data on mechanical circulatory support implants to the registry. Data for all implants in paediatric patients (≤19 years of age) performed from 1 January 2000 to 31 December 2017 were analysed. This report includes updates of patient characteristics, implant frequency, outcome (including mortality rates, transplants and recovery rates) as well as adverse events. RESULTS: Twenty-five hospitals contributed 237 registered implants in 210 patients (81 ♀, 129 ♂) to the registry. The most frequent diagnosis was any form of cardiomyopathy (71.4%) followed by congenital heart disease (18.6%). Overall mean support time on a device was 11.6 months (±16.5 standard deviation). A total of 173 children (82.4%) survived to transplant, recovery or are ongoing; 37 patients (17.6%) died while on support within the observed follow-up time. At 12 months 38% of patients received transplants, 7% were weaned from their device and 15% died. At 24 months, 51% of patients received transplants, 17% died while on support, 22% were on a device and 9% were explanted due to myocardial recovery. The adverse events rate per 100 patient-months was 11.97 for device malfunction, 2.83 for major bleeding, 2.83 for major infection and 1.52 for neurological events within the first 3 months after implantation. CONCLUSIONS: The first paediatric EUROMACS report reveals a low transplant rate in European countries within the first 2 years of implantation compared to US data. The 1-year survival rate seems to be satisfactory. Device malfunction including pump chamber changes due to thrombosis was the most frequent adverse event.
引用
- de By TMMH, Schweiger M, Waheed H, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): first EUROMACS Paediatric (Paedi-EUROMACS) report. Eur J Cardiothorac Surg. 2018. PMID: 30184070. doi:10.1093/ejcts/ezy298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。